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Abstract
Introduction: Ulcerative colitis (UC) require expensive, lifelong treatment, which generates huge direct costs and has 
a significant impact on the quality of life, especially in the active state of the disease.
Aim: To assess the indirect costs, health-related quality of life, and clinical characteristics of patients with UC in Poland. 
Additionally, we investigated the association between activity of UC and productivity loss of patients in a Polish setting.
Material and methods: A questionnaire survey was conducted using the Patient Simple Clinical Colitis Activity Index (P-SCCAI) 
to assess disease activity, as well as the modified Work Productivity and Activity Impairment Questionnaire to assess produc-
tivity loss. The quality of life was presented as utility calculated with the EQ-5D-3L questionnaire. Indirect costs were assessed 
with the Human Capital Approach and were expressed in Polish zlotys (PLN) as well as in euros (€). Correlations were presented 
using the Spearman coefficient. 
Results: We performed our analysis based on 202 full questionnaires collected. Mean patient age and age at disease on-
set were 33.14 years (standard deviation (SD): 9.90) and 26.35 years (SD: 8.89), respectively. The mean P-SCCAI score in the 
analysed group of patients was 8.26, and the mean utility was 0.8651. Average and median annual indirect costs per working 
person were €2043 and €1389 (8543 PLN and 5808 PLN), respectively, calculated using the gross domestic product, as well as 
€4791 and €3257 (20,026 PLN and 13,615 PLN), respectively, calculated using the gross value added. Total productivity loss was 
significantly correlated with the disease activity. 
Conclusions: Ulcerative colitis causes a decrease in the quality of life as well as patients’ productivity loss associated with 
both absenteeism and with presenteeism. 
Introduction
Ulcerative colitis (UC) is an idiopathic inflammatory 
bowel disorder characterised by an inflammatory re-
action involving the colonic mucosa [1, 2]. The clinical 
course is unpredictable and marked by alternating pe-
riods of exacerbations and remissions, which may oc-
cur spontaneously or in response to treatment changes 
or intercurrent illnesses [3, 4]. The prevalence of UC 
in Europe ranges from 4.9 to 505 per 100,000 people, 
while in North America it ranges from 37.5 to 248.6 
per 100,000 people [5]. People affected with UC require 
expensive, lifelong treatment, which generates great 
direct costs to the national health insurance system. 
Additionally, it has a significant impact on the quality of 
life, especially in the active state of the disease. Ulcera-
tive colitis is assumed to impose a considerable medical 
and societal burden, but there are no studies that would 
investigate both the quality of life and direct or indirect 
costs in a Polish setting. A recent review on that topic 
[6] showed that only 18 studies on the indirect costs of 
inflammatory bowel diseases in general were carried 
out worldwide, while only one was for UC.
The activity of UC is assessed with the Patient Sim-
ple Clinical Colitis Activity Index (P-SCCAI) [7], while the 
quality of life among patients with the disease can be 
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measured using the EuroQol questionnaire five-dimen-
sion, three-level version (EQ-5D-3L).
The P-SCCAI is a patient-based translated version of 
the SCCAI questionnaire, which is used by clinicians to 
quantify disease activity of UC. The SCCAI refers to dis-
ease symptoms during the previous week. It consists of 
the following domains: bowel frequency during the day 
and during the night, urgency of defecation, blood in 
stool, general well-being, and a number of defined extra-
colonic features of UC. The clinician-based SCCAI is able 
to categorise two types of patients: those with inactive 
disease/remission (SCCAI score < 5) and those with active 
disease (SCCAI score ≥ 5) [7]. As in the case of the SCCAI 
questionnaire, the P-SCCAI refers to symptoms during the 
previous week. It was translated into language that is un-
derstandable for patients, and the medical terminology 
and disease symptoms were clarified. The interpretation 
of results is the same as in the SCCAI questionnaire [7].
The indirect costs that follow UC are associated with 
absence from work (absenteeism) and a decrease in the 
efficiency of work done by the sick patient (presentee-
ism). Absenteeism refers to the number of days on sick 
leave, periods of unemployment caused by a disease, 
and early leaving of the labour market due to sickness 
(e.g. early retirement or early death). Leaving the labour 
market due to early death is rather not calculated in the 
case of UC because there is no evidence that patients 
with UC have shorter life expectancy. Presenteeism re-
fers to a situation when a sick person is present at work 
but his or her own productivity is lower than average 
due to the disease [8].
The Work Productivity and Activity Impairment 
(WPAI) questionnaire is a well-validated instrument 
to measure impairments in work and activities and is 
a standard analytic tool commonly used to assess ab-
senteeism and presenteeism in a number of diseases [9]. 
Each category of indirect costs (absenteeism, presentee-
ism) can be calculated using two methods: the human 
capital approach (HCA) and the friction cost approach 
(FCA). The HCA converts the gross income that will not be 
earned in the future due to disease into real costs from 
a social perspective; hence it assumes that a decrease in 
productivity is permanent (irreplaceable). The FCA takes 
into account productivity losses until a new person is 
employed as a substitute for the sick one.
Aim
The aim of this study was to assess the indirect 
costs, health-related quality of life, and clinical charac-
teristics of patients with UC measured by a UC disease 
activity index in Poland. The second aim was to investi-
gate the association between disease activity and pro-
ductivity loss of affected patients in a Polish setting.
Material and methods 
A questionnaire-based survey was used to collect 
data on disease activity, health-related quality of life, 
and productivity loss of UC patients in Poland. The sur-
vey was started in October 2015 and has been planned 
to be finalised at the end of the first quartile of 2016. 
The results presented in this study are preliminary with 
a cut-off date of 31 December 2015, when a threshold 
population of the above 200 patients was reached. The 
study was performed in a group of patients with a diag-
nosis of UC, in cooperation with the Polish Association 
Supporting People with Inflammatory Bowel Disease 
“J-elita” (j-elita.org.pl). Patients filled in the paper ver-
sion of the questionnaire regarding the disease activity 
index (P-SCCAI), comorbidities, prescribed treatment for 
UC, basic characteristics (age, sex, work status, date of 
disease onset, place of living, working status), disability 
status (EQ-5D-3L), expenses on medical and non-med-
ical resources (e.g. private medical consultation, over-
the-counter medication and dietary supplements, 
information materials) and loss of productivity (presen-
teeism, absenteeism), informal care, and benefits from 
a social care institution due to UC. Respondents were 
allowed to return the questionnaire by traditional mail, 
e-mail (scanned version), or saved directly on the server 
dedicated for this study (scanned version). 
To assess the health-related quality of life, the Eu-
roQol five-dimension, three-level version (EQ-5D-3L) 
questionnaire was used [10], and it was evaluated with 
the Polish norms presented by Golicki et al. [11]. The 
EQ-5D-3L takes into account five of the most important 
aspects of life: mobility, self-care, housekeeping activi-
ties, pain, and anxiety. For each domain the patient can 
report a lack of problems (represented by digit 1), the 
occurrence of some problems (digit 2), and the occur-
rence of many problems (digit 3). Data obtained using 
the EQ-5D-3L questionnaire can be converted into util-
ity using population tariffs [8].
The WPAI questionnaire [10] was the starting point 
for the preparation of the part of the questionnaire 
concerning loss of productivity (presenteeism, absen-
teeism), usual activity impairment, informal care, and 
benefits from a social care institution; it was modified 
to adapt the questionnaire to part-time and seasonal 
employees, patients on rehabilitation benefit or other 
temporally inactive patients, or those awaiting the as-
sessment of incapacity for work. 
The HCA was used to estimate indirect costs due 
to absenteeism and presenteeism. Two macroeconom-
ic indicators for Poland were considered: gross domes-
tic product per capita (GDP, €10,688 or 44,677 PLN) 
and gross value added (GVA, €25,055 or 104,728 PLN) 
per worker presented in 2014 prices in euro (the ex-
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change rate used was 1 euro = 4.18 PLN, which was 
the average exchange rate in 2015) with a correction 
factor of 0.65 (the conventional mean value of out-
put elasticity of labour according to the Cobb-Doug-
las function of production; this approach is suggested 
by the European Commission because increasing the 
amount of a single factor of production, with all other 
factors of production constant, decreased the marginal 
output of a production) [12, 13]. The GDP per capita 
is a commonly used measure of a country’s econom-
ic development. Its weakness is that it considers not 
only employees but also people who are economically 
inactive, such as children and retirees. It was calcu-
lated by dividing the GDP for Poland in the year 2014 
(1,719,097 million PLN) by the Polish population in the 
same year (38,478,600; the above values come from 
the Central Statistical Office of Poland, www.stat.gov.
pl). The GVA per worker reflects true economic devel-
opment in areas of production. It is expressed as value 
per worker and does not consider economically inac-
tive people. The GVA per worker has been recognised 
as the most appropriate measurement for examining 
the decrease in human capital due to illness, as it rep-
resents the productivity of a country in all econom-
ic sectors. It was calculated by dividing the GVA for 
Poland in 2014 (1,525,193 million PLN) by the Polish 
population in the same year. 
Statistical analysis
Continuous variables were summarised using 
means and standard deviations (SDs) or median and 
interquartile range (IQR), while nominal variables were 
summarised using counts and percentages. The Spear-
man’s correlation was used to present the association 
between disease activity and absenteeism as well as 
presenteeism. P-values of less than 0.05 indicated sta-
tistical significance. Additionally, data on disease ac-
tivity and generated indirect costs were presented on 
scatterplots. Absenteeism was presented as the number 
of days missed from work per year, while presenteeism 
was expressed as the percentage of standard work ef-
ficiency achieved due to UC. Statistical analyses were 
performed using Statistica®.
Results
We obtained 202 completed questionnaires from 
patients aged from 18 to 71 years (average age was 
33.14 years, SD: 9.90; median value was 31.00 years). 
The basic characteristics of the population are present-
ed in Table I.
Of 202 patients, 190 (94.1%) provided data on dis-
ease activity with the P-SCCAI questionnaire. Based on 
those values, the mean P-SCCAI score was 8.26 (SD: 
5.26; range: 0–24). Among 190 patients with UC, 26.3% 
had remission according to the P-SCCAI score. Patients 
also assessed disease activity on their own, based on the 
clinician’s opinion during the last consultation. The com-
pliance of patient’s own assessment with the P-SCCAI 
score was 53.4%.
Patients reported between 0 and 10 consultations 
with a clinician during the month before completing the 
questionnaire with a mean value of 1.22 (SD: 1.71), of 
which 62.12% were private visits with an average cost 
of the consultation of 141.69 PLN (SD: 59.99).
About 55.5% of patients spent from 0 to 100 PLN 
monthly on drugs prescribed by the clinician, and only 
3.47% spent more than 600 PLN monthly. A similar 
amount of money was spent on dietary supplements and 
other medicines that are not prescribed by the clinician 
(over-the-counter drugs). The smallest amount of money 
was spent monthly on information materials about the 
disease: more than 90% of patients spent from 0 to 100 
PLN, and no patient spent more than 400 PLN.
Almost 96% of patients (193 of 202) provided infor-
mation about the drugs used. The vast majority of pa-
tients (92.23%) took mesalazine. The other often admin-
istered drugs were: azathioprine (26.94%), prednisone 
or prednisolone (21.24%), and sulfasalazine (13.47%). 
Only 4.66% of patients declared to use biologic drugs: 
adalimumab (2.59%) and infliximab (2.07%). Only 11 pa- 
tients had surgery due to UC, which was restorative 
proctocolectomy in the majority of cases.
A number of UC patients (27.8%) required help with 
daily activities; in 95.5% of cases, the help was provid-
ed by family members. Only 11.2% of patients received 
financial benefits from state institutions in the form of 
disability pension, social pension, illness or rehabilita-
Table I. The basic characteristics of the population considered in the study
Characteristic N Value
Age [years] 202 33.14 (SD: 9.90), range: 18–71
Male 198 75 (37.88%)
Disease onset [years] 201 26.35 (SD: 8.89), range: 8–62
Place of living City < 100,000 citizens 200 60 (30.00%)
City ≥ 100,000 citizens 119 (59.50%)
Village 21 (10.50%)
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tion benefit, and 8.4% received financial support from 
other sources.
Data on employment status was collected for 202 
patients, of which 150 (74.26%) were currently work-
ing. Among all working patients, 130 were on full-time 
contract. Thirty-four (16.83%) patients were still stud-
ying and 6.44% did not have paid employment. Only 
7 patients were on pension due to UC and seven were 
unable to work. The average monthly amount of social 
pension was 605.75 PLN, and it was slightly lower than 
pension due to inability to work (681.25 PLN). 
The average annual number of days off work due 
to illness was 30.49 (SD: 65.37; range: 0–279). Most 
people (65.31%) reported lack of days off work due to 
the disease. 
The relationship between absenteeism and disease 
activity (moderate correlation of 0.4603 with a p-value 
of less than 0.05) is presented in Figure 1.
Average on-the-job productivity loss was 19.38% 
(SD: 23.64%; range: 0–100%), which represents the ex-
tent of presenteeism. Only 4.1% of working patients 
reported on-the-job productivity loss of at least 70%, 
while 44.8% of working patients reported no on-the-job 
productivity loss (value 0). Data were presented for 145 
working patients with UC; five working patients did not 
provide data on on-the-job productivity loss.
The relationship between presenteeism and dis-
ease activity (moderate correlation of 0.4194 with 
a p-value of less than 0.05, which indicates statistical 
significance) is presented in Figure 2. Loss of on-the-
job productivity was positively correlated with disease 
activity. 
Using the GDP per capita, the indirect costs of 
absenteeism per working person were €679 (SD: 
€1691) or 2837 PLN (SD: 7070 PLN), and the indirect 
costs of presenteeism per working person were 1346 
(SD: €1642; median: €695, IQR: €1642) or 5628 PLN 
(SD: 6864 PLN; median: 2904 PLN, IQR: 6864 PLN). Tak-
ing into account the GVA per worker, the costs were as 
follows: €1591 (SD: €3965) or 6651 PLN (SD: 16,573 PLN) 
for absenteeism, and €3156 (SD: €3849; median: 
€1629, IQR: €3849) or 13,192 PLN (SD: 16,089 PLN; 
median: 6807 PLN, IQR: 16,089 PLN) for presenteeism.
The average annual indirect cost of both absentee-
ism and presenteeism per working person was €2043 
(SD: 2876; median: €1389, IQR: 3215) or 8543 PLN 
(SD: 12,020; median: 5808 PLN, IQR: 13,441) calculated 
using the GDP and €4791 (SD: 6,741; median: €3257, 
IQR: 7537) or 20,026 PLN (SD: 28,178; median: 13,615 
PLN, IQR: 31,507) calculated using the GVA. Data were 
based on the answers of 144 working patients with UC. 
The cost of presenteeism accounted for 65.87% of the 
total indirect costs. 
As a sensitivity analysis, the results without the 
correction factor (marginal productivity of labour) were 
presented. Total annual indirect costs per patient were 
€2989 (SD: €3801) or 12,495 PLN (SD: 15,887 PLN), 
as calculated using the GDP, and €7007 (SD: €8910) 
or 29,289 PLN (SD: 37,242 PLN), as calculated using 
the GVA.
The relationship between indirect costs calculated 
using the GDP and disease activity (moderate correla-
tion of 0.4651 with p-value of less than 0.05) is present-
ed in Figure 3. The correlation of disease activity with 
indirect costs calculated using the GVA was the same.
Data on the quality of life were also reported by 
almost all respondents (201 of 202; 99.5%). Based 
on data from Table II, the health states were created. 
The most common state was “11122”, reported by 
58 (28.86%) patients. The highest (worst) state ob-
served was “22222” and occurred in 3 (1.49%) patients. 
Based on these data the utility was calculated using 
the Polish tariff [14]. The mean utility equalled 0.8651 
(SD: 0.1285; range: 0.1720–1). 
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Discussion
This study examined the impact of UC on the work 
productivity of affected patients. Despite the fact that UC 
is known to impose a high clinical and societal burden, 
there is no evidence to confirm this in Poland. Our study 
proved that UC reduces the quality of life, especially in pa-
tients with active disease. The study also showed that the 
greater the disease activity, the lower the quality of life. 
Moreover, UC generates significant indirect costs, mainly 
due to presenteeism. We observed a significant moderate 
correlation between disease activity and indirect costs.
There have been no previous attempts to assess 
the indirect costs of UC in Poland. Therefore, it seems 
necessary to assess the societal burden of the disease 
on a representative group of patients in Poland, using 
a comprehensive approach. Additionally, the avail-
able data suggest that there may be significant be-
tween-country differences in health-related quality of 
life of the same population, and the differences may 
even lead to changing the conclusions of economic 
evaluations [15]. In the absence of reliable information 
on the health-related quality of life of UC in Poland, 
there was a need to conduct such an assessment. 
Our project involved the assessment of the indirect 
costs of both absenteeism and presenteeism, based on 
our own survey questionnaire. The methodology used 
and the results obtained provide novel data that fill the 
information gap. However, our study has several limi-
tations, and the results are preliminary and should be 
interpreted with caution. They may be used as the basis 
for further, more sophisticated studies. 
The major limitation is the recruitment of patients. 
The sample size was reasonably good, but the methods 
for the inclusion of respondents without randomised al-
location provided results that are not fully representative 
of the whole UC population. In the analysed group of pa-
tients there was a slight overrepresentation of women; 
however, the observed difference in sex structure for UC 
proved insignificant. We also recorded a high percentage 
of individuals who live in big cities (with 100,000 citi-
zens or more) and a small percentage of village citizens, 
which might have influenced labour market activity and 
might have affected our results. Data on disease activity 
were provided by patients, not by clinicians, which may 
be another limitation. However, the agreement between 
self- assessment by patients and the P-SCCAI score was 
quite good and equalled 53.4%. 
In order to compare our results with findings of other 
investigators, we performed a review of medical data-
bases. We discovered no studies considering the indirect 
costs of UC in Poland. However, we identified a system-
atic review performed by Kawalec and Malinowski (2015) 
[6], indicating that only 18 studies on the indirect costs of 
inflammatory bowel diseases were conducted worldwide: 
six studies on Crohn’s disease (CD), only one for UC, and 
11 on inflammatory bowel diseases in general. The iden-
tified study concerning UC [16] (available as an abstract) 
considered only lost wages from time away from work 
due to disability and medically-related absenteeism. 
Total annual indirect costs were calculated to be 4087 
USD (2010 values; €4070 in 2015 values). It is difficult to 
compare our results with the results of the above study 
[16] because it was performed in a different setting and 
it concerned only privately insured U.S. employees. 
One study was additionally identified concerning 
the indirect costs of selected inflammatory diseases in 
Poland, the ‘Move to Work’ or M2W study [17]. The aim 
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Table II. Quality of life assessment in the considered population
Life domain Problems reported with specific life domains
No Some A lot
Mobility 179 (89.05%) 22 (10.95%) 0 (0%)
Self-care 197 (98.01%) 4 (1.99%) 0 (0%)
Usual activities 149 (74.13%) 49 (24.38%) 3 (1.49%)
Pain 69 (34.33%) 127 (63.18%) 5 (2.49%)
Anxiety 67 (33.33%) 124 (61.69%) 10 (4.98%)
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of this study was to assess the indirect costs of rheu-
matoid arthritis, psoriasis and Crohn disease (CD) in 
Poland. The study involved 2100 patients from Poland, 
including 464 with CD. The results of the study indicat-
ed that the highest indirect cost associated with absen-
teeism was among patients with rheumatoid arthritis, 
and the lowest was among patients with psoriasis. It 
was found that the lowest cost associated with presen-
teeism was generated by patients with CD. The annual 
indirect cost per working patient with CD was estimat-
ed at 10,414 PLN (absenteeism: €2491) and 13,187 
(presenteeism: €3155). The M2W study included only 
patients undergoing outpatient visits (inpatient care 
was excluded), and in contrast to other illnesses, more 
than 60% of patients with CD were in remission or the 
disease had very low activity. Narrowing the included 
population resulted in the study being unrepresentative. 
Conclusions
People affected with UC require expensive, lifelong 
treatment, which constitutes a great burden to the na-
tional health insurance system. The UC generates con-
siderable indirect costs, mainly due to lower productivi-
ty at work, but also due to absenteeism. The greater the 
disease activity, the greater the indirect costs generated 
by the disease. The UC causes a significant decrease in 
patient’s quality of life.
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